Ribociclib With Switch Endocrine Therapy Beneficial Even After CDK4/6 Progression for HR+/HER2– Breast Cancer - Targeted Oncology

Treatment with ribociclib and an alternate endocrine therapy after progression on a prior CDK4/6 inhibitor improved progression-free survival over placebo and endocrine therapy in patients with HR-positive, HER2-negative unresectable or metastatic breast canc…
Treatment with ribociclib (Kisqali), and an alternate endocrine therapy, after progression on a prior CDK4/6 inhibitor showed a 43% reduction in the risk of progression or death compared with placebo… [+8164 chars] Read More